http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 09 Dec 2025 06:56:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html <p>Fosun Pharma (SSE: 600196; HKEX: 02196) announced that its subsidiary Yao Pharma has entered into an exclusive collaboration and license agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of oral small-molecule GLP-1 receptor agonists.</p> <p>Under the agreement, Yao Pharma grants Pfizer worldwide exclusive rights to develop, manufacture and commercialize YP05002 and related oral GLP-1R agonist products for therapeutic, diagnostic and prophylactic uses in both human and veterinary applications. The license covers all indications for these treatments.</p> <p>Yao Pharma will receive an upfront payment of $150 million and is eligible for milestone payments up to $1.935 billion based on development, http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html Tue, 09 Dec 2025 06:56:00 -0500 02196 2196 600196 O.00000313 O.03976764 PFE http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html <p>Fosun Pharma (SSE: 600196; HKEX: 02196) announced that its subsidiary Yao Pharma has entered into an exclusive collaboration and license agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of oral small-molecule GLP-1 receptor agonists.</p> <p>Under the agreement, Yao Pharma grants Pfizer worldwide exclusive rights to develop, manufacture and commercialize YP05002 and related oral GLP-1R agonist products for therapeutic, diagnostic and prophylactic uses in both human and veterinary applications. The license covers all indications for these treatments.</p> <p>Yao Pharma will receive an upfront payment of $150 million and is eligible for milestone payments up to $1.935 billion based on development, http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html Tue, 09 Dec 2025 06:56:00 -0500 02196 2196 600196 O.00000313 O.03976764 PFE http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html <p>Fosun Pharma (SSE: 600196; HKEX: 02196) announced that its subsidiary Yao Pharma has entered into an exclusive collaboration and license agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of oral small-molecule GLP-1 receptor agonists.</p> <p>Under the agreement, Yao Pharma grants Pfizer worldwide exclusive rights to develop, manufacture and commercialize YP05002 and related oral GLP-1R agonist products for therapeutic, diagnostic and prophylactic uses in both human and veterinary applications. The license covers all indications for these treatments.</p> <p>Yao Pharma will receive an upfront payment of $150 million and is eligible for milestone payments up to $1.935 billion based on development, http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html Tue, 09 Dec 2025 06:56:00 -0500 02196 2196 600196 O.00000313 O.03976764 PFE http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html <p>Fosun Pharma (SSE: 600196; HKEX: 02196) announced that its subsidiary Yao Pharma has entered into an exclusive collaboration and license agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of oral small-molecule GLP-1 receptor agonists.</p> <p>Under the agreement, Yao Pharma grants Pfizer worldwide exclusive rights to develop, manufacture and commercialize YP05002 and related oral GLP-1R agonist products for therapeutic, diagnostic and prophylactic uses in both human and veterinary applications. The license covers all indications for these treatments.</p> <p>Yao Pharma will receive an upfront payment of $150 million and is eligible for milestone payments up to $1.935 billion based on development, http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html Tue, 09 Dec 2025 06:56:00 -0500 02196 2196 600196 O.00000313 O.03976764 PFE http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html <p>Fosun Pharma (SSE: 600196; HKEX: 02196) announced that its subsidiary Yao Pharma has entered into an exclusive collaboration and license agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of oral small-molecule GLP-1 receptor agonists.</p> <p>Under the agreement, Yao Pharma grants Pfizer worldwide exclusive rights to develop, manufacture and commercialize YP05002 and related oral GLP-1R agonist products for therapeutic, diagnostic and prophylactic uses in both human and veterinary applications. The license covers all indications for these treatments.</p> <p>Yao Pharma will receive an upfront payment of $150 million and is eligible for milestone payments up to $1.935 billion based on development, http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html Tue, 09 Dec 2025 06:56:00 -0500 02196 2196 600196 O.00000313 O.03976764 PFE http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html <p>Fosun Pharma (SSE: 600196; HKEX: 02196) announced that its subsidiary Yao Pharma has entered into an exclusive collaboration and license agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of oral small-molecule GLP-1 receptor agonists.</p> <p>Under the agreement, Yao Pharma grants Pfizer worldwide exclusive rights to develop, manufacture and commercialize YP05002 and related oral GLP-1R agonist products for therapeutic, diagnostic and prophylactic uses in both human and veterinary applications. The license covers all indications for these treatments.</p> <p>Yao Pharma will receive an upfront payment of $150 million and is eligible for milestone payments up to $1.935 billion based on development, http://www.streetinsider.com/Corporate+News/Fosun+Pharma+unit+partners+with+Pfizer+on+obesity+drug+development/25714685.html Tue, 09 Dec 2025 06:56:00 -0500 02196 2196 600196 O.00000313 O.03976764 PFE http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/Press+Releases/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, <span>Chongqing Yao Pharmaceutical Company, Limited</span>. ("Yao Pharma"), <span>Shanghai Fosun Pharmaceutical Industrial Development Company Limited</span>, and <span value="NYSE:PFE" idsrc="xmltag.org" >Pfizer Inc.</span> (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants <span value="NYSE:PFE" idsrc="xmltag.org">Pfizer</span> an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license http://www.streetinsider.com/PRNewswire/Fosun+Pharma%27s+Subsidiary+Yao+Pharma+and+Pfizer+Enter+into+Exclusive+Collaboration+and+License+Agreement/25714683.html Tue, 09 Dec 2025 06:55:00 -0500 02196 2196 600196 600196 O.00000313 O.03976764 PFE PFE http://www.streetinsider.com/Press+Releases/Fosun+Pharma+Announces+2025Q3+Financial+Results/25509387.html <div class="xn-content"> <p class="prntac"> <b>Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding <money>RMB6,700 Million</money> in The First Three Quarters of 2025</b> </p> <p> http://www.streetinsider.com/Press+Releases/Fosun+Pharma+Announces+2025Q3+Financial+Results/25509387.html Tue, 28 Oct 2025 08:11:00 -0500 02196 2196 600196 600196 A.06822034 A.19158983 A.29246800 O.00159422 O.03976764 O.20026344 O.50899713 http://www.streetinsider.com/Press+Releases/Fosun+Pharma+Announces+2025Q3+Financial+Results/25509387.html <div class="xn-content"> <p class="prntac"> <b>Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding <money>RMB6,700 Million</money> in The First Three Quarters of 2025</b> </p> <p> http://www.streetinsider.com/Press+Releases/Fosun+Pharma+Announces+2025Q3+Financial+Results/25509387.html Tue, 28 Oct 2025 08:11:00 -0500 02196 2196 600196 600196 A.06822034 A.19158983 A.29246800 O.00159422 O.03976764 O.20026344 O.50899713 http://www.streetinsider.com/Press+Releases/Fosun+Pharma+Announces+2025Q3+Financial+Results/25509387.html <div class="xn-content"> <p class="prntac"> <b>Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding <money>RMB6,700 Million</money> in The First Three Quarters of 2025</b> </p> <p> http://www.streetinsider.com/Press+Releases/Fosun+Pharma+Announces+2025Q3+Financial+Results/25509387.html Tue, 28 Oct 2025 08:11:00 -0500 02196 2196 600196 600196 A.06822034 A.19158983 A.29246800 O.00159422 O.03976764 O.20026344 O.50899713